Thus, the scope of this review is to provide an integrative overview of evidence, in particular from clinical studies and human samples, on the role of AMPK in the regulation of primarily de novo lipogenesis in human NAFLD. Here, PRKAA1 is linked to metabolic dysfunction-associated steatotic liver disease.